Böger, Rainer H.

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study

Zoccali, C., Bode-Böger, S. M., Mallamaci, F., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I., Fermo, I., Frölich, J. C., et al. (2001) · The Lancet

Nitric Oxide and Endothelin EffectsDialysis and Renal Disease Management

Cited by 1,087

Pharmacokinetic and pharmacodynamic properties of oral L‐citrulline and L‐arginine: impact on nitric oxide metabolism

Schwedhelm, E., Maas, R., Freese, R., Jung, D., Lukacs, Z., Jambrecina, A., Spickler, W., Schulze, F., & Böger, R. H. (2008) · British Journal of Clinical Pharmacology

Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

Cited by 494

Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the “L-Arginine Paradox” and Acts as a Novel Cardiovascular Risk Factor

Böger, R. H. (2004) · The Journal of Nutrition

Nitric Oxide and Endothelin EffectsCancer-related gene regulation

Cited by 363

Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production

Böger, R. H., Bode-Böger, S. M., Mügge, A., Kienke, S., Brandes, R., Dwenger, A., & Frölich, J. C. (1995) · Atherosclerosis

Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

Cited by 252

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

Schieffer, B., Bünte, C., Witte, J., Hoeper, K., Böger, R. H., Schwedhelm, E., & Drexler, H. (2004) · Journal of the American College of Cardiology

Renin-Angiotensin System StudiesEicosanoids and Hypertension Pharmacology

Cited by 239

Endogenous nitric oxide synthase inhibitors are responsible for the L‐arginine paradox

Tsikas, D., Böger, R. H., Sandmann, J., Bode-Böger, S. M., & Frölich, J. C. (2000) · FEBS Letters

Nitric Oxide and Endothelin EffectsCancer-related gene regulation

Cited by 237

The Pharmacodynamics of L-Arginine

Böger, R. H. (2007) · The Journal of Nutrition

Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

Cited by 221

Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality

Böger, R. H., Maas, R., Schulze, F., & Schwedhelm, E. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM)

Nitric Oxide and Endothelin EffectsCancer-related gene regulation

Cited by 65

The L-Arginine–Asymmetric Dimethylarginine Ratio is an Independent Predictor of Mortality in Dilated Cardiomyopathy

Anderssohn, M., Rosenberg, M., Schwedhelm, E., Zugck, C., Lutz, M., Lüneburg, N., Frey, N., & Böger, R. H. (2012) · Journal of Cardiac Failure

Nitric Oxide and Endothelin EffectsHeart Failure Treatment and Management

Cited by 44

ADMA and arginine derivatives in relation to non-invasive vascular function in the general population

Baum, C., Johannsen, S. S., Zeller, T., Atzler, D., Ojeda, F. M., Wild, P. S., Sinning, C. R., Lackner, K. J., Gori, T., Schwedhelm, E., et al. (2016) · Atherosclerosis

Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

Cited by 21